Abiraterone Acetate

abiraterone acetate is a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.

Indications

:- metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel.

Dosage

oral; 1000mg once daily with prednisone. Take empty stomach

Contra-Indications

pregnancy

Special Precautions

Paediatric: Safety not yet established Pregnancy: Category X; Contraindicated Lactation: Not to be given Elderly: Safety similar to adult

Side Effects

joint swelling or discomfort, hypokalemia, edema, muscle discomfort, hot flush, diarrhea, urinary tract infection, cough, hypertension, arrhythmia, urinary frequency, nocturia, dyspepsia, and upper respiratory tract infection.

Drug Interactions

Avoid co-administration with CYP2D6 substrates that have a narrow therapeutic index.